Meeting
2017 ASCO Annual Meeting
An open-label, phase Ib study of NEO-PV-01 + adjuvant with nivolumab in patients with melanoma, non-small cell lung carcinoma, or transitional cell carcinoma of the bladder.
Authors
Aung Naing
Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX
Aung Naing , Siwen Hu-Lieskovan , Ramaswamy Govindan , Kim Allyson Margolin , Melissa Ann Moles , Richard Gaynor , Matthew Jordan Goldstein , Patrick Alexander Ott
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research,Immunotherapy
Sub Track
Vaccines
Clinical Trial Registration Number
NCT02897765
Citation
J Clin Oncol 35, 2017 (suppl; abstr TPS3116)
DOI
10.1200/JCO.2017.35.15_suppl.TPS3116
Abstract #
TPS3116
Poster Bd #
198b
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Final results: Dose escalation study of a personalized peptide-based neoantigen vaccine in patients with metastatic melanoma.
First Author: Sofie Kirial Mørk
Poster
2022 ASCO Annual Meeting
A pilot trial of neoantigen DNA vaccine in combination with nivolumab/ipilimumab and prostvac in metastatic hormone-sensitive prostate cancer (mHSPC).
First Author: Koral Shah
Poster
2023 ASCO Annual Meeting
H3.3-K27M neoantigen vaccine elicits anti-tumor T cell immunity against diffuse intrinsic pontine glioma: The phase I ENACTING trial.
First Author: Yang Zhang
Poster
2023 ASCO Annual Meeting
Effect of personalized immunization with GNOS-PV02 of patients with hepatocellular carcinoma on TCR clonal expansion, tumor infiltration, and vaccine-specific reactivity.
First Author: Renzo Perales